These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28500260)

  • 1. Anticoagulation therapy for thromboembolism prevention: a case of warfarin-induced skin necrosis in the setting of protein C deficiency.
    Lai J; Ramai D; Alchi R; Bloomfield D
    BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28500260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin-Induced Skin Necrosis in Patients With Low Protein C Levels.
    Marčić M; Marčić L; Titlić M
    Acta Med Iran; 2016 Aug; 54(8):551-554. PubMed ID: 27701728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late onset warfarin-induced skin necrosis.
    Xin C; Hu D; Li M
    G Ital Dermatol Venereol; 2019 Apr; 154(2):205-208. PubMed ID: 25410444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reinstituting warfarin in patients who develop warfarin skin necrosis.
    Jillella AP; Lutcher CL
    Am J Hematol; 1996 Jun; 52(2):117-9. PubMed ID: 8638632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.
    Nakase T; Moroi J; Ishikawa T
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1174-1177. PubMed ID: 29276013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical warfarin-induced skin necrosis.
    Ward CT; Chavalitanonda N
    Pharmacotherapy; 2006 Aug; 26(8):1175-9. PubMed ID: 16863494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated guidelines on outpatient anticoagulation.
    Wigle P; Hein B; Bloomfield HE; Tubb M; Doherty M
    Am Fam Physician; 2013 Apr; 87(8):556-66. PubMed ID: 23668445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin-induced skin necrosis associated with Factor V Leiden and protein S deficiency.
    Ng T; Tillyer ML
    Clin Lab Haematol; 2001 Aug; 23(4):261-4. PubMed ID: 11683790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.
    Menon N; Sarode R; Zia A
    Blood Adv; 2018 Jan; 2(2):142-145. PubMed ID: 29365322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
    PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late-onset warfarin-induced skin necrosis: case report and review of the literature.
    Essex DW; Wynn SS; Jin DK
    Am J Hematol; 1998 Mar; 57(3):233-7. PubMed ID: 9495376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.